Pfizer Deal Sweetens Onyx Pot
Onyx's deal with Pfizer will be a sweetener as bidding for the biotech gets more intense, says Adam Feuerstein, senior columnist at TheStreet.
Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.
